Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société REGENERON PHARMACEUTICALS
12:01pForty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talen..
PR
09:31aFda accepts for review libtayo in combination with chemotherapy for first-line treatmen..
AQ
01/19FDA Accepts for Review Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy for ..
PR
01/19Second Positive Phase 3 Dupixent® (dupilumab) Trial Confirms Significant Improvements f..
PR
01/13Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results a..
PR
01/10Regeneron and ultragenyx collaborate to commercialize evkeeza (evinacumab) outside the ..
AQ
01/10REGENERON PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulatio..
AQ
01/07Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evinacumab) Outside the..
PR
2021Regeneron Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference
PR
2021Results mixed on monoclonal antibody use against Omicron variant
AQ
2021REGENERON PHARMACEUTICALS : Next Generation Monoclonal Antibodies are Active Against All K..
PU
2021Dupixent - positive phase 3 dupixent data in children 6 months to 5 years with moderate..
AQ
2021Regeneron - new regn5458 phase 1 data show 75% response rate at highest dose levels stu..
AQ
2021Regeneron - new england journal of medicine publishes positive phase 3 dupixent results..
AQ
2021New England Journal of Medicine Publishes Positive Phase 3 Dupixent® (dupilumab) Result..
PR
2021Regeneron to participate in h.c. wainwright and co. virtual event
AQ
2021Regeneron to Participate in H.C. Wainwright & Co. Virtual Event
PR
2021Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
AQ
2021REGENERON PHARMACEUTICALS : Evaluating REGEN-COV® and Next Generation Antibodies against N..
PU
2021Regeneron Announces Investor Conference Presentations
PR
2021Regeneron antibody cocktail approved by european commission to treat and prevent covid-..
AQ
2021Regeneron announces $3 billion share repurchase program
AQ
2021Regeneron Listed on Dow Jones Sustainability World Index for Third Consecutive Year
PR
2021Regeneron Announces $3 Billion Share Repurchase Program
PR
2021Regeneron Antibody Cocktail Approved by European Commission to Treat and Prevent COVID-..
PR
2021CHMP Recommends EU Approval of Regeneron Antibody Cocktail to Treat and Prevent COVID-1..
PR
2021Regeneron Pharmaceuticals - NEW PHASE 3 ANALYSES SHOW THAT A SINGLE DOSE OF REGEN-COV (..
AQ
2021Regeneron says antiviral COVID-19 cocktail shows protection after 8 months
AQ
2021Regeneron presentations at ash highlight expanding clinical research in blood cancers a..
AQ
2021Regeneron Corporate Presentation November 2021
PU
2021Regeneron Reports Third Quarter 2021 Financial and Operating Results - Form 8-K
PU
2021REGENERON PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
AQ
2021REGENERON : Q3 Earnings Snapshot
AQ
2021REGENERON PHARMACEUTICALS : Second dupixent (dupilumab) phase 3 eosinophilic esophagitis t..
AQ
2021REGENERON PHARMACEUTICALS : Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis ..
PR
2021REGENERON PHARMACEUTICALS : Fda expands approval of dupixent (dupilumab) to include childr..
AQ
2021REGENERON PHARMACEUTICALS : FDA Expands Approval of Dupixent® (dupilumab) to Include Child..
PR
2021REGENERON PHARMACEUTICALS : FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priorit..
PR
2021REGENERON PHARMACEUTICALS : to Report Third Quarter 2021 Financial and Operating Results a..
PR
2021REGENERON PHARMACEUTICALS : New regen-cov (casirivimab and imdevimab) data show supportive..
AQ
2021REGENERON PHARMACEUTICALS : New england journal of medicine publishes positive phase 3 tri..
AQ
2021REGENERON PHARMACEUTICALS : Fda accepts libtayo (cemiplimab-rwlc) for priority review for ..
AQ
2021REGENERON PHARMACEUTICALS : FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for..
PR
2021REGENERON PHARMACEUTICALS : Welcomes World Health Organization Recommendation for Use of R..
PU
2021REGENERON PHARMACEUTICALS : New dupixent (dupilumab) data in patients as young as six year..
AQ
2021REGENERON PHARMACEUTICALS : New Dupixent® (dupilumab) Data in Patients as Young as Six Yea..
PR
2021REGENERON PHARMACEUTICALS : Esmo late-breaking data show libtayo (cemiplimab) and chemothe..
AQ
2021SANOFI : - ESMO late-breaking data show Libtayo (cemiplimab) and chemotherapy first-line t..
AQ
2021REGENERON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
2021REGENERON PHARMACEUTICALS : Announces new u.s. government agreement to purchase additional..
AQ
2021REGENERON PHARMACEUTICALS : Announces New U.S. Government Agreement to Purchase Additional..
PR
2021REGENERON PHARMACEUTICALS : Announces Investor Conference Presentations
PR
2021REGENERON PHARMACEUTICALS : Announces Encouraging Topline Phase 2 Data of High-dose aflibe..
PR
2021REGENERON PHARMACEUTICALS : Uk authorizes regeneron antibody cocktail to prevent and treat..
AQ
2021REGENERON PHARMACEUTICALS : UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat..
PR
2021REGENERON PHARMACEUTICALS : DeSantis top donor invests in COVID drug governor promotes
AQ
2021REGENERON PHARMACEUTICALS : Reports second quarter 2021 financial and operating results
AQ
2021REGENERON PHARMACEUTICALS : Phase 3 trial of libtayo combined with chemotherapy stopped ea..
AQ
2021REGENERON PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AN..
AQ
2021REGENERON : Q2 Earnings Snapshot
AQ
2021REGENERON PHARMACEUTICALS : Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chem..
PR
2021REGENERON PHARMACEUTICALS : Announces the 2021 Winners of the Prize for Creative Innovatio..
PR
2021REGENERON PHARMACEUTICALS : FDA Expands Authorized Use of REGEN-COV™ (casirivimab an..
PR
2021REGENERON PHARMACEUTICALS : Dupixent significantly improved itch and hives in patients wit..
AQ
2021REGENERON PHARMACEUTICALS : Dupixent® (dupilumab) Significantly Improved Itch and Hives in..
PR
2021REGENERON PHARMACEUTICALS : And astrazeneca to research develop and commercialize new smal..
AQ
2021REGENERON PHARMACEUTICALS : and AstraZeneca to Research, Develop and Commercialize New Sma..
PR
2021REGENERON PHARMACEUTICALS : Japan Becomes First Country to Approve Regeneron Antibody Cock..
PR
2021REGENERON PHARMACEUTICALS : to Report Second Quarter 2021 Financial and Operating Results ..
PR
2021REGENERON PHARMACEUTICALS : Genetics Center Discovers GPR75 Gene Mutations that Protect Ag..
PR
2021REGENERON PHARMACEUTICALS : - dupixent (dupilumab) smpc updated with long-term data reinfo..
AQ
2021SANOFI : - Libtayo approved by the European Commission as the first immunotherapy indicate..
AQ
2021REGENERON PHARMACEUTICALS : Libtayo® (cemiplimab) Approved by the European Commission as t..
PR
2021REGENERON PHARMACEUTICALS : Libtayo® (cemiplimab) Approved by the European Commission for ..
PR
2021REGENERON PHARMACEUTICALS : to Participate in Guggenheim Biopharma Strategy Series
PR
1  2  3  4  5  6  7  8  9  10Next
Official Publications
Upcoming event on REGENERON PHARMACEUTICALS